SCHEMBL20058030

SCHEMBL20058030

CCCc1ccc(-c2ccc(NC)cc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 1/20 0.46
KIF11 P52732 1/20 0.45
MCL1 Q07820 1/20 0.42
LPL P06858 1/20 0.42
LIPG Q9Y5X9 1/20 0.42
NISCH Q9Y2I1 1/20 0.41
HRH3 Q9Y5N1 2/20 0.40
NPC1 O15118 1/20 0.40
MAPT P10636 1/20 0.40
RAB9A P51151 1/20 0.40
GFER P55789 1/20 0.40
CA2 P00918 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
RARB P10826 2/20 0.39
ACACB O00763 1/20 0.39
ACACA Q13085 1/20 0.39
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12452414 0.93 PLK1 (0.50) PLK1LPLLIPGCA2ALDH1A1
SCHEMBL19829477 0.86 RARB (0.54) LPLLIPGHRH3MAPTALDH1A1
SCHEMBL9418558 0.84 LPL (0.43) PLK1MCL1LPLLIPGNISCH
SCHEMBL4802707 0.83 LPL (0.54) PLK1MCL1LPLLIPGNISCH
SCHEMBL18664826 0.82 UCHL1 (0.53) PLK1KIF11NPC1MAPTRAB9A
SCHEMBL2098522 0.80 PLK1 (0.53) PLK1NPC1RAB9ACA2ALDH1A1
Hydrochloric Acid SCHEMBL28291713 0.79 CA2 (0.41) PLK1MCL1LPLLIPGNISCH
SCHEMBL22951099 0.78 HRH3 (0.47) PLK1MCL1LPLLIPGNISCH
Hydrochloric Acid SCHEMBL2863755 0.78 PLK1 (0.52) PLK1NPC1RAB9ACA2ALDH1A1
SCHEMBL27496644 0.78 ESR1 (0.55) LPLLIPGCA2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3309150-A1 BIPHENYL-ETHYL-PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR MODULATORS FOR THE TREATMENT OF COGNITIVE DISORDERS Arena Pharmaceuticals, Inc. (US) 2018-04-18 EP disclosed